• Nanomedicine and nano-enabled therapeutic systems

• Biomaterials engineering for targeted and controlled drug delivery

• Design, formulation, and in-vitro, ex-vivo, and in-vivo characterisation of:

  • Nanoemulsions

  • Polymeric and lipid-based nanocarriers

  • Injectable and stimuli-responsive hydrogels

  • Microneedle-based drug delivery systems

  • Biomaterial scaffolds for regenerative medicine

• Enhancement of drug solubility, bioavailability, stability, and site-specific delivery

• Targeted therapeutic strategies for cancer, inflammatory and infectious diseases, neurological disorders, and skin-related conditions

• Integration of formulation science with pharmacokinetic evaluation and therapeutic performance assessment

• Translational nanomedicine bridging fundamental research and clinically relevant applications

• Teaching in the areas of:

  • Pharmaceutics and pharmaceutical technology

  • Nanomedicine and drug delivery systems

  • Biomaterials and biomedical engineering

• Undergraduate and postgraduate instruction in:

  • Formulation design and development

  • Physicochemical and rheological characterisation

  • Preclinical evaluation and translational research

• Supervision and mentoring of MSc and PhD students

• Interdisciplinary teaching integrating materials science, biology, and pharmacology

• Research-led teaching approaches, including:

  • Experimental design and data interpretation

  • Scientific writing and publication ethics

Dr. Sabya Sachi Das is a MSCA (Marie Skłodowska-Curie Actions) Postdoctoral Fellow at the Bernal Institute, University of Limerick, Ireland. His research focuses on nanomedicine, biomaterials engineering, and targeted drug delivery, with particular emphasis on the development of liposome-based immunotheranostic platforms for cancer and their translational and preclinical evaluation.

He obtained his Ph.D. in Pharmacy from the Birla Institute of Technology, India, where his doctoral work involved the development and pharmacokinetic evaluation of quercetin-loaded nanoemulsions using integrated in vitro, ex vivo, and in vivo approaches. He subsequently held postdoctoral research positions at the University of North Carolina at Charlotte and the University of Iowa, USA, working on nanotechnology-based drug delivery systems and advanced therapeutic platforms.

He has broad expertise in nanomedicine, encompassing the design and development of lipid- and polymer-based nanoparticle systems, advanced biomaterials, and targeted drug delivery platforms, with a strong emphasis on bioanalytical and pharmacokinetic evaluation for translational applications. He has authored over 75 peer-reviewed publications and 25 book chapters, with more than 3,000 citations, and has been recognized among the world’s top 2% scientists (Stanford University & Elsevier, 2023-2025). His research aims to bridge fundamental nanotechnology with clinically relevant therapeutic applications.